JAK2 and neoplasm: Among the most relevant actionable findings, we found a simultaneous amplification of PDL1, PDL2, and JAK2 (9p24.1) in a patient with a sigmoid colon adenocarcinoma, which is a rare genomic event reported in 0.7% of 187 tumor samples of >100 tumor types, including the presence of this marker in 0.